1-241504162-T-G
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PP3_StrongPP5
The ENST00000366560.4(FH):c.988A>C(p.Thr330Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T330A) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000366560.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FH | NM_000143.4 | c.988A>C | p.Thr330Pro | missense_variant | 7/10 | ENST00000366560.4 | NP_000134.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FH | ENST00000366560.4 | c.988A>C | p.Thr330Pro | missense_variant | 7/10 | 1 | NM_000143.4 | ENSP00000355518 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 08, 2023 | This sequence change replaces threonine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 330 of the FH protein (p.Thr330Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with hereditary leiomyomatosis and/or renal cell cancer (PMID: 16309500, 16403393, 31444830, 34654685; Invitae). This variant is also known as T287P. ClinVar contains an entry for this variant (Variation ID: 575043). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FH protein function with a positive predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 15, 2024 | The p.T330P pathogenic mutation (also known as c.988A>C), located in coding exon 7 of the FH gene, results from an A to C substitution at nucleotide position 988. The threonine at codon 330 is replaced by proline, an amino acid with highly similar properties. This alteration was identified in a 50-year-old woman, who had uterine fibroids and cutaneous leiomyomata (Chuang GS et al. Clin. Exp. Dermatol., 2006 Jan;31:118-21). Additionally, this alteration was identified in an individual diagnosed with an FH-deficient renal cell carcinoma (Zhang L et al. Hum Mutat, 2020 01;41:103-109). It has also been reported in an individual with early-onset renal cancer (Truong H et al. Eur Urol Oncol. 2021 Dec;4(6):993-1000 and an individual with PGL/PCC (Zavoshi S. et al Urology. 2023 Jun;176:106-114). This alteration has been observed in multiple individuals with a personal and/or family history that is consistent with FH-related disease (Ambry internal data; external communication). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 22, 2023 | Variant summary: FH c.988A>C (p.Thr330Pro) results in a non-conservative amino acid change located in the Fumarate lyase, N-terminal (IPR022761) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251276 control chromosomes (gnomAD). c.988A>C has been reported in the literature in individuals affected with Hereditary Leiomyomatosis And Renal Cell Cancer (Kim_2005, Chuang_2006, Zhang_2020). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 16403393, 16309500, 31444830, 34654685, 34994643). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Both submitters classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at